Summary by Moomoo AI
Ardelyx, Inc., a biopharmaceutical company, announced the filing of its DEF 14A proxy statement with the U.S. Securities and Exchange Commission (SEC), detailing the upcoming annual meeting of stockholders scheduled for June 14, 2024. The meeting will be held entirely online, allowing stockholders to listen live and vote on key proposals. The agenda includes the election of two Class I directors, approval of amended equity and employee stock purchase plans, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024. The proxy statement also outlines the company's corporate governance practices, director compensation, and equity compensation plans. Stockholders as of April 15, 2024, are eligible to vote at the meeting. The board recommends voting 'FOR' all proposals, including the election of director nominees, the approval of the equity incentive and employee stock purchase plans, the advisory approval of named executive officer compensation, and the ratification of the accounting firm.